Jan B Pietzsch1, Shan Liu1,2, Abigail M Garner1, Eric J Kezirian3, Patrick J Strollo4. 1. Wing Tech Inc., Menlo Park, CA. 2. University of Washington, Seattle, WA. 3. Keck School of Medicine of the University of Southern California, Los Angeles, CA. 4. University of Pittsburgh, PA.
Abstract
STUDY OBJECTIVES: Upper airway stimulation (UAS) is a new approach to treat moderate-to-severe obstructive sleep apnea. Recently, 12-month data from the Stimulation Treatment for Apnea Reduction (STAR) trial were reported, evaluating the effectiveness of UAS in patients intolerant or non-adherent to continuous positive airway pressure therapy. Our objective was to assess the cost-effectiveness of UAS from a U.S. payer perspective. DESIGN: A 5-state Markov model was used to predict cardiovascular endpoints (myocardial infarction [MI], stroke, hypertension), motor vehicle collisions (MVC), mortality, quality-adjusted life years (QALYs), and costs. We computed 10-year relative event risks and the lifetime incremental cost-effectiveness ratio (ICER) in $/QALY, comparing UAS therapy to no treatment under the assumption that the STAR trial-observed reduction in mean apnea-hypopnea index from 32.0 to 15.3 events/h was maintained. Costs and effects were discounted at 3% per year. SETTING: U.S. healthcare system; third-party payer perspective. PARTICIPANTS: 83% male cohort with mean age of 54.5 years. INTERVENTIONS: UAS vs. no treatment. MEASUREMENTS AND RESULTS: UAS substantially reduced event probabilities over 10 years (relative risks: MI 0.63; stroke 0.75; MVC 0.34), and was projected to add 1.09 QALYs over the patient's lifetime. Costs were estimated to increase by $42,953, resulting in a lifetime ICER of $39,471/QALY. CONCLUSIONS: Relative to the acknowledged willingness-to-pay threshold of $50,000-$100,000/QALY, our results indicate upper airway stimulation is a cost-effective therapy in the U.S. healthcare system.
STUDY OBJECTIVES: Upper airway stimulation (UAS) is a new approach to treat moderate-to-severe obstructive sleep apnea. Recently, 12-month data from the Stimulation Treatment for Apnea Reduction (STAR) trial were reported, evaluating the effectiveness of UAS in patients intolerant or non-adherent to continuous positive airway pressure therapy. Our objective was to assess the cost-effectiveness of UAS from a U.S. payer perspective. DESIGN: A 5-state Markov model was used to predict cardiovascular endpoints (myocardial infarction [MI], stroke, hypertension), motor vehicle collisions (MVC), mortality, quality-adjusted life years (QALYs), and costs. We computed 10-year relative event risks and the lifetime incremental cost-effectiveness ratio (ICER) in $/QALY, comparing UAS therapy to no treatment under the assumption that the STAR trial-observed reduction in mean apnea-hypopnea index from 32.0 to 15.3 events/h was maintained. Costs and effects were discounted at 3% per year. SETTING: U.S. healthcare system; third-party payer perspective. PARTICIPANTS: 83% male cohort with mean age of 54.5 years. INTERVENTIONS:UAS vs. no treatment. MEASUREMENTS AND RESULTS:UAS substantially reduced event probabilities over 10 years (relative risks: MI 0.63; stroke 0.75; MVC 0.34), and was projected to add 1.09 QALYs over the patient's lifetime. Costs were estimated to increase by $42,953, resulting in a lifetime ICER of $39,471/QALY. CONCLUSIONS: Relative to the acknowledged willingness-to-pay threshold of $50,000-$100,000/QALY, our results indicate upper airway stimulation is a cost-effective therapy in the U.S. healthcare system.
Authors: Nathaniel S Marshall; Keith K H Wong; Peter Y Liu; Stewart R J Cullen; Matthew W Knuiman; Ronald R Grunstein Journal: Sleep Date: 2008-08 Impact factor: 5.849
Authors: B M Psaty; C D Furberg; L H Kuller; M Cushman; P J Savage; D Levine; D H O'Leary; R N Bryan; M Anderson; T Lumley Journal: Arch Intern Med Date: 2001-05-14
Authors: Jeffrey A Cutler; Paul D Sorlie; Michael Wolz; Thomas Thom; Larry E Fields; Edward J Roccella Journal: Hypertension Date: 2008-10-13 Impact factor: 10.190
Authors: George T O'Connor; Brian Caffo; Anne B Newman; Stuart F Quan; David M Rapoport; Susan Redline; Helaine E Resnick; Jonathan Samet; Eyal Shahar Journal: Am J Respir Crit Care Med Date: 2009-03-05 Impact factor: 21.405
Authors: C McDaid; S Griffin; H Weatherly; K Durée; M van der Burgt; S van Hout; J Akers; R J O Davies; M Sculpher; M Westwood Journal: Health Technol Assess Date: 2009-01 Impact factor: 4.014
Authors: Scott D Ramsey; Lauren D Clarke; Craig S Roberts; Sean D Sullivan; Scott J Johnson; Larry Z Liu Journal: Pharmacoeconomics Date: 2008 Impact factor: 4.981
Authors: Winfried Randerath; Jan de Lange; Jan Hedner; Jean Pierre T F Ho; Marie Marklund; Sofia Schiza; Jörg Steier; Johan Verbraecken Journal: ERJ Open Res Date: 2022-06-27
Authors: Kingman P Strohl M D; Jonathan Baskin M D; Colleen Lance M D; Diana Ponsky M D; Mark Weidenbecher M D; Madeleine Strohl B A; Motoo Yamauchi M D Journal: Respir Investig Date: 2016-03-18
Authors: Anvesh R Kompelli; Jonathan S Ni; Shaun A Nguyen; Eric J Lentsch; David M Neskey; Ted A Meyer Journal: World J Otorhinolaryngol Head Neck Surg Date: 2018-09-25